

Studying of Some Immunological Parameters in Patients with Inflammatory Bowel Disease (IBD) in Al-Anbar Province

Thikra Majid Muhammed AL-Obaidy*,¹, Hasan Ali Mutar², and Thaeer Abdulqader Salih³

¹ Department of Biology, College of Sciences, University of Anbar, Ramadi, Iraq

² Department of Animal Production, College of Agriculture, University of Anbar, Ramadi, Iraq

³ Department of Biology, College of Education for Pure Sciences, University of Anbar, Ramadi, Iraq



ARTICLE INFO

Received: 8/ 1/2021

Accepted: 4/3/2021

Available online: 1/6/2021

DOI: 10.37652/juaps.2022.172396

Keywords:

p ANCA, *c NCA*, *IL-17A*,
IL-17F.

Copyright©Authors, 2021, College of Sciences, University of Anbar. This is an open-access article under the CC BY 4.0 license (<http://creativecommons.org/licenses/by/4.0/>).



A B S T R A C T

The serum levels of interleukin-17A and interleukin-17F were determined using ELISA technique for quantitative determination of IL-17A and IL-17F concentrations in serum. A comparison in Immunological parameters between the two groups (patients and control) showed that there was a significant difference in levels of IL-17 A and IL-17F with p-value (<0.05). The means were: IL-17 A (79.29 pg/ml), (18.72 pg/ml) and IL-17F(226.4 pg/ml), (29.09 pg/ml) respectively. Also the serum levels of p ANCA and c ANCA were determined using Enzyme-linked immunosorbent assay ELISA technique for quantitative determination of pANCA and c ANCA concentrations in human serum. There was a significant difference in levels of perinuclear antineutrophil cytoplasmic antibodies (pANCA) and cytoplasmic antineutrophil cytoplasmic antibodies(c ANCA) with p-value(<0.05), the means were: pANCA (60.93 ng/ml), (10.31ng/ml), and c ANCA (35.78 ng/ml), (8.341ng/ml) respectively.

1. INTRODUCTION

Immunity is one of the physiological processes that can be split into innate and adaptive immunity in human beings. To recognize 'self' and 'non-self' elements, the human body relies on immunity; therefore the immunity protects humans against invasion of pathogens. The use of a wide collection of different pattern recognition receptors and a mechanism for random and non-selective production of specific antigen receptors are two major processes of innate immunity. Adaptive immunity has been seen as a supplement to innate immunity and a conclusive solution to pathogen recognition [1].

Cells are related to inflammatory bowel disease pathogenesis as they are inherently plastic to the provocation of the surrounding state [2].

A potent pro-inflammatory factor in IBD is the Th17 cells that manufacture IL-17. In the study, IL-17 expression and IL-17A and IL-17F levels in the mucosa and serum of IBD patients were higher than in healthy controls [3,4].

Various Th17-related cytokines were found to be upregulated compared to normal subjects in UC and CD patients, but they were higher in UC patients [5,6].

*Corresponding author at: Department of Biology - College of Sciences - University of Anbar; E-mail address: thikraalobaidy91@gmail.com

The antigen P-ANCA responds to is usually myeloperoxidase (MPO) [7]. Other neutrophil elements, including the material granules azurophil (elastase, cathepsin G and antimicrobial cationic protein), minor granules (lactoferrin) and cytosolic proteins such as a-enolase, may be targets of autoantibodies [8,9].

Myeloperoxidase (MPO) is a large cationic molecule consisting of a heterodimer with a molecular weight (MW) of about 140kDa, which represents about 5% of the total protein content of neutrophils. The enzyme is characterized by a powerful bactericidal function, the peroxidase activity of which is physiologically inhibited by ceruloplasmin [10].

Proteinase 3(PR3) is a serine protease within the azurophil granules of neutrophils and monocyte lysosomes with elastin lytic and other functional activities. Proteinase 3 is almost always the C-ANCA reaction antigen [8,9,11].

Proteinase 3(PR3) is a weak molecular weight cationic protein (MW) (29-30 kDa) that belonging to the serine protease family of trypsin. PR3 is synthesized as a preproenzyme and subsequently processed into mature form in four stages. It is stored in neutrophil azurophilic granules but can also be located inside the secretory vesicle membrane, and it is physiologically inhibited by α 1-antitrypsin [12].

In conjunction with IBD, a third main subgroup of ANCA, often denoted to as "atypical" which is now known

as xANCA This is a form of P-ANCA that is not myeloperoxidase-reactive, Usually demonstrates a pattern of combined perinuclear and cytoplasmic staining, a broad array of non-MPO p-ANCA antigen specificities are described (e.g. elastase, lysozyme), each with subtle variations in staining (which may class them as atypical) [8,9,11,13].

The term atypical p-ANCA should be considered as a misnomer and substituted by the more appropriate term antineutrophil nuclear antibodies (ANNA) [14].

As a mixture of c-ANCA and p-ANCA, the atypical pattern of ANCA is characterized as fine rim-like staining with intranuclear foci or large non-homogeneous rim-like staining of the nuclear periphery [15,16].

Atypical ANCA testing may be a useful test in this particular population to distinguish CD from UC. Previous studies indicated that atypical p-ANCA is a useful parameter to differentiate CD from UC [17].

In 1966, Faber and Elling first documented IBD-associated ANCA, which described the existence of leukocyte-specific antinuclear factors in patients with ulcerative colitis [17].

This discovery was not generalized until 1983, when granulocyte-specific antinuclear antibodies were also found in patients with ulcerative colitis and Crohn's disease by Nielsen and associates [19].

Perinuclear staining is produced by P-ANCA. C-ANCA and P-ANCA react with cytoplasmic antigens by definition. The perinuclear distribution of staining caused by P-ANCA on alcohol-fixed neutrophils is the product of antigen rearrangement from the cytoplasm to the nucleus during substrate preparation [20].

C-ANCA and P-ANCA (including IBD P-ANCA) stain neutrophil cytoplasm when neutrophils are fixed with formalin that immobilizes the antigens, rather than with alcohol. However, the role of ANCA in IBD may still be controversial, particularly in ambiguous cases. A previous study found a link with disease activity. ANCA may predict the development of IBD years before it is clinically diagnosed at the early age of the onset of disease, fibro stenosis, internal fistulas, and perianal disease and ileal involvement [21,22,23].

2. METHODOLOGY

2.1. Patients and Controls

The study included (60) patients of different ages (15-60) who were suffering of inflammatory bowel disease, and attended general teaching hospital in Ramadi city in Al-Anbar governorate during the period extended from the 1st of May 2020 to the 1st of January 2021. The samples of patients were selected according to the diagnosis of gastroenterologists. While control included (40) healthy persons of different ages (15-60) years. They were classified as a negative test group because after examination by

gastroenterologists they did not show a history of inflammatory bowel disease.

From an acceptable vein, 10 ml of venous blood was obtained. Tourniquet was applied above the selected venipuncture site around (4-5) finger width and disinfected by 70% of ethanol for 30 seconds and allowed to dry completely, the blood was divided into two type of tubes, the first one; 2.5 ml whole blood was dispensed in tow tubes with ethylene diamine tetra acetic acid tube (EDTA-tube) and mixed gently. In the second tube; the residual part of the blood sample was transferred to it (free of anticoagulation) and allowed to coagulate for serum separation using centrifuge at (4000 rpm) for 5 minutes. The separated serum was collected in a sterile clean white tube for serological studies. The tubes were then placed in an aseptic cool-box and deposited in the freezer at (-20°C) before further processing [24].

2.2. Diagnostic Kits and Chemical Reagents

The following diagnostic kits and chemical reagents were used:

Serum levels of interleukine-17A and interleukine-17F commercially available Enzyme Linked Immuno Sorbent Assay (ELISA) kits (Biosource InC, USA) were used for quantitative determination of IL-17A and IL-17F concentrations by micro plate Enzyme immunoassay in human serum which based on similar principle. Human Perinuclear Anti-Neutrophil Cytoplasmic Antibody (pANCA) ELISA Kit (Abbexa InC, UK) was used for quantitative measurement of pANCA concentration by micro plate Enzyme immunoassay in human serum. Human anti-neutrophil cytoplasmic antibody (cANCA) sandwich ELISA kit (Abbexa InC, UK) was used for quantitative determination of human anti-neutrophil cytoplasmic antibody (also known as cANCA) concentration by micro plate Enzyme immunoassay in human serum.

3. RESULTS AND DISCUSSION

The total number of persons included in the study was (100) samples which included (60) patients were found to have inflammatory bowel disease (cases) and (40) normal persons as control.

3.1. Immunological Data Analysis

3.1.1. levels of IL-17A and IL-17 F

The present study showed significant increase in IL-17A levels in patients with IBD (cases) compared with persons without IBD (control) with p-value (<0.05) and the mean for IL-17A incases higher than control The means for their groups of IL-17A were (79.29 pg/ml), (18.72 pg/ml) as shown in figure(3-1), respectively.




Fig. (3-1): Mean levels of IL-17A (pg/ml) in patients and controls Std. Deviation: Control=1.743, patient =17.03.

The present study showed significant increase in IL-17F levels in patients with IBD (cases) compared with persons without IBD (control) with p-value (<0.05) and the mean for IL-17F in cases higher than control the means for their groups of IL-17F were (226.4 pg/ml),(29.09 pg/ml) respectively as shown in figure(3-2).




Fig. (3-2): Mean levels of IL-17F (pg/ml) in patients and controls . Std. Deviation: Control=9.359, patient =49.78

The present study showed significant differences in level of IL-17 A and F in cases and control.

IL-17A and IL-17F share (60%) among the members of the IL-17 family of cytokines. They are normally expressed by Th17 [25].

IL-17A and IL-17F share similar functions as members of the IL-17 family, especially in terms of their ability to induce the expression of chemokine which is important for neutrophil recruitment and activation [26].

The most studied cytokines which are responsible for the pathogenic activity of Th17 cells are IL-17A and IL-17F [27].The present study is concordant with the study of [28]which showed in patients with UC, the IL-17 concentration was substantially higher than that in controls. The present study is also in agreement with the study of

Jiang et al. [29] that showed an increased in serum and intestinal tissue levels in IL-17 and Th17 cells in IBD patients..

Several studies have moreover recently indicated that raised serum IL-17 levels are related to an enlarged risk of UC [28] that does consistent with the present study. In inflammatory bowel disease (IBD) immunopathogenesis, cytokines plays an important role, including Crohn's disease and ulcerative colitis, where many aspects of intestinal inflammation are driven and regulated, The imbalance between proinflammatory and anti-inflammatory cytokines that occur in IBD contributes to disease progression and damage to tissue and limits inflammation resolution [30]. By macrophage activation, IL-17 can stimulate the development of cytokines and chemokines in endothelial cells, thus contributing to neutrophil recruitment and inflammation [31].In addition, serum IL-17 levels have been significantly correlated with the severity of IBD, suggesting that serum IL-17 may be closely linked to the progression of the disease to inflammation and reasonable explanations for this association may be that IL-17 mutations change the stability of a higher number of related pro-inflammatory cytokines secreted into the serum of UC patients [32].

3.1.2. Levels of p-ANCA and c-ANCA

The present study showed significantly increase in levels of p-ANCA in cases compared with control with p-value was (< 0.05)- and the means of p-ANCA for two groups were (60.93 ng/ml), (10.31ng/ml) respectively as shown in figure (3-3).




Fig. (3-3): Mean levels of pANCA (ng/ml) in patients and control. Std. Deviation: Control= 3.189, patient = 17.41

The present study showed significantly increase in levels of c-ANCA in cases compared with control with p-value was (< 0.05). and the means of c-ANCAfor two groups were (35.78 ng/ml),(8.341ng/ml) respectively as shown in figure (3-4).




Fig. (3-4): Mean levels of cANCA (ng/ml) in patients and controls. Std. Deviation: Control= 2.876, patient = 5.817

ANCAs are autoantibodies against neutrophil granules and monocyte lysosomes, including p-ANCA and c-ANCA, and serum p-ANCA was first identified as a diagnostic tool to diagnose and treat IBD [33].

ANCA test might be a good test for the diagnosis of UC and differentiating UC from CD. The specificity of-ANCA for diagnosing was 97%[34] . The present study is consistent with the study of Prideaux *et al.* [35] which showed the highest prevalence of p-ANCA was demonstrated in patients with IBD.

The outcome of multiple comparisons showed that the seropositivity of pANCA was substantially higher in patients with moderate and serious disease than in those with mild disease [36].

Nevertheless, the prevalence of pANCA was 50 (70%) in UC patients, 6 (20%) in CD patients and 1 (2.5%) in healthy individuals [37].

Several studies showed a correlation between p-ANCA serum levels and UCA intensity- [38] that are consistent with current study

Atypical p-ANCA are found at high prevalences in patients with IBD, they represent a potentially valuable diagnostic seromarker for these disorders [39] that does also consistent with present study.

The present study is also consistent with the study of Rutgeerts and Vermeire, [40] which showed in the serum of patients with IBD, p-ANCA has been observed, the prevalence of positive p-ANCA in UC ranges from 40 to 80%.

Another study showed with extensive colitis and positive C-ANCA serology the cases were eight patients (more than 40%) were also PR3-positive, whereas the other 10 were PR3-negative [41].

The presence of many forms of antibodies in the serum of IBD patients demonstrates the immune-mediated existence of IBD; tissue damage and antibody development occur in IBD as a result of gene mutation-based dysregulated innate immunity; several antibodies with

distinct antigenic specificities are generated, the role of these antibodies in IBD pathogenesis is uncertain. To date, serological antibodies tend to be likely to be indicators of an irregular immune response rather than direct effectors involved in disease pathogenesis [42].

Autoimmunity to neutrophils can facilitate tissue damage via numerous mechanisms [43].

In patients with these complaints, ANCA can cause a respiratory burst and degranulation of neutrophils which have been primed by cytokines ; The preactivation or priming of neutrophils is associated with the translocation of certain granule contents to the surface membrane, including ANCA target antigens, where autoantibodies are available, Degranulation and release of neutrophils can then directly damage or contribute to the development of an immune complex in the vascular endothelium; proteinase 3 can also provide a proliferative T cell response [44] .

In addition, ANCA may be a predictor of inherited susceptibility to ulcerative colitis, demonstrated first by the discovery of an increased prevalence of ANCA in the unaffected family members of sera-using patients with ulcerative colitis. ANCA recognition is also a potential predictor of the immunological disorder underlying these conditions [45].

Nevertheless, previous studies have indicated that p-ANCA may be a responsive and specific test for diagnosing UC, separating it from Crohn's disease and other colitids, and offering a prognosis for medical care response and risk of paucities after the pelvic pouch [46].

While the present study is not consistent with the study of Peeters *et al.* [47] which showed there was no relationship between the patients and control of ANCA tests.

Moreover, the study of Abu-Freha *et al.* [48] founded prevalence of ANCA and pANCA in Arab Bedouin IBD patients.

By contrast this study does not agreement with the study of Saibeniand Gborsi [49]. Which confirms the low prevalence of p-ANCA observed in ulcerative colitis patients. That does not consist with present study.

The present study also not consistent with the study of Zhou *et al.* [50] which showed there was no statement on ANCA prevalence in Taiwanese patients with IBD.

4. CONCLUSIONS

A significant increase in IL-17A and IL-17F in patients with IBD more than control. Significant increase was noticed in p ANCA and c ANCA in patients more than control.

REFERENCES

- [1] McCurley N., Hirano M., Das S., and Cooper M. (2012)."Immune related genes underpin the evolution of adaptive immunity in jawless vertebrates. *Curr*

- Genomics". 13; 86-94.
- [2] Murphy K., and Stockinger B. (2010). "Effector T cell plasticity: flexibility in the face of changing circumstances". *Nat Immunol.*11;674-680.
- [3] Fujino S., Andoh A., and Bamba S. (2003). "Increased expression of interleukin 17 in inflammatory bowel disease". *Gut.* 52;65- 70.
- [4] Seiderer J., Elben I., and Diegelmann J. (2008). "Role of the novel Th17 cytokine IL-17F in inflammatory bowel disease (IBD): upregulated colonic IL-17F expression in active Crohn's disease and analysis of the IL17F p.His161Arg polymorphism in IBD". *Inflamm Bowel Dis.*14;437-445.
- [5] Kobayashi T., Okamoto S., and Hisamatsu T. (2008). "IL23 differentially regulates the Th1/Th17 balance in ulcerative colitis and Crohn's disease". *Gut.*57;1682-1689.
- [6] Raza A., and Shata M. (2012). "Letter: pathogenicity of Th17 cells may differ in ulcerative colitis compared with Crohn's disease". *Aliment Pharmacol Ther.*36;204.
- [7] Halbwachs L., Nusbaum P., and Noel L. (1992). "Antineutrophil cytoplasmic antibodies (ANCA) directed against cathepsin G in ulcerative colitis, Crohn's disease and primary sclerosing cholangitis". *Clin Exp Immunol.*90;79-84.
- [8] Kain R., Matsui K., and Exner M. (1995). "A novel class of autoantigens of anti-neutrophil cytoplasmic antibodies in necrotizing and crescentic glomerulonephritis: the lysosomal membrane glycoprotein h-lamp-2 in neutrophil granulocytes and a related membrane protein in glomerular endothelial cells". *Journal of Experimental Medicine.*181(2);585-597.
- [9] Savige J., Davies, D., and Gatenby P. (1994). "Anti-neutrophil cytoplasmic antibodies (ANCA): their detection and significance: report from workshops". *Pathology.*26(2);186-193.
- [10] Kallenberg C., Shoenfeld Y., Gershwin M., and Meroni P. (2007). "Antineutrophil antibodies with specificity for Myeloperoxidase in Autoantibodies". Elsevier, Oxford, UK. 2nd edition;95-103.
- [11] Jennette J. (1991). "Anti-neutrophil cytoplasmic autoantibody-associated disease: A pathologist's perspective". *Am J Kidney Disease.*18;164-170.
- [12] Radice A., Sabadini E., and Sinico A. (2007). "Antineutrophil antibodies with specificity for Proteinase 3. in Autoantibodies". Elsevier, Oxford, UK, 2nd edition;105-110.
- [13] Kaneko K., Suzuki Y., Yamashiro Y., Yabuta K. (1993). "Is pANCA in ulcerative colitis directed against b-glucuronidase?" *Lancet*;341: 320.
- [14] Birgit T., Ulrich S., Tilman S., and Howard J. (2000). "Atypical p-ANCA in IBD and Hepatobiliary Disorders React With a 50-Kilodalton Nuclear Envelope Protein of Neutrophils and Myeloid Cell Lines." *Gastroenterology*.119;310-322.
- [15] Papp M., Altorjay I., Lakos G., Tumppek J., Sipka S., Dinya T. (2009). "Evaluation of the combined application of ethanol-fixed and formaldehyde-fixed neutrophil substrates for identifying atypical perinuclear antineutrophil cytoplasmic antibodies in inflammatory bowel disease. *Clin Vaccine Immunol*".16(4);464-70.
- [16] Lochman I., Kral V., Lochmanova A., Lupač J., and Cebecauer L. (2011). "ANCA in the diagnosis of neutrophil-mediated inflammation. *Autoimmun Rev.*10;295-8.
- [17] Mokhtarifar A., Ganji A., Sadrneshin M., Bahari A., Esmaeilzadeh A., and Ghafarzadegan K. (2013). "Diagnostic value of ASCA and atypical p-ANCA in differential diagnosis of inflammatory bowel disease". *Middle East J Dig Dis.*5;93-7.
- [18] Faber V., Elling P. (1967). "Leukocyte-specific antinuclear factors in patients with Felty's syndrome, rheumatoid arthritis, systemic lupus erythematosus and other diseases". *Acta Med Scand.*179;257.
- [19] Nielsen H., Wiik A., and Elmgreen J. (1983). "Granulocyte specific antinuclear antibodies in ulcerative colitis". *Acta Pathol Microbiol Immunol Scand.*91;23.
- [20] Charles L., Falk R., and Jennette J. (1989). "Reactivity of anti-neutrophil cytoplasmic autoantibodies with HL-60 cells. *Clin Immunol Immunopathol.*53;243.
- [21] Israeli E., Grotto I., Gilburd B., Balicer R., Goldin E., and Wiik A. (2005). "Anti-Saccharomyces cerevisiae antibodies as predictors of inflammatory bowel disease". *Gut.*54;1232-6.
- [22] Vasiliauskas E., Kam L., Karp L., Gaiennie J., Yang H., Targan S. (2000). "Marker antibody expression stratifies Crohn's disease into immunologically homogenous subgroups with distinct clinical characteristics". *Gut.*47;487-96.
- [23] Zhang L., Ren J., Wong C., Wu W., Ren S., and Shen J. (2012). "Effects of cigarette smoke and its active components on ulcer formation and healing in the gastrointestinal mucosa". *Curr Med Chem.*19;63-9.
- [24] Cadman H. (2010). Aspect of phlebotomy. In: WHO guidelines on drawing blood: best practices in phlebotomy. *Sign*;8-47.
- [25] Yang X., Panopoulos A., and Nurieva R. (2007). "STAT3 regulates cytokine-mediated generation of inflammatory helper T cells". *J. Biol. Chem.*282(13); 9358-9363.
- [26] Hyun Y., Han D., Lee A., Eun C., Youn J., and Kim H. (2012). "Role of IL-17A in the development of colitis-associated cancer. *Carcinogenesis*".33; 931-936.

- [27] Afzali B., Lombardi G., Lechler R., Lord G. (2007). "The role of T helper 17 (Th17) and regulatory T cells (Treg) in human organ transplantation and autoimmune disease". *Clin Exp Immunol.*148; 32-46
- [28] Ohman L., Dahlén R., Isaksson S., Sjöling A., Wick M., Sjövall H., Van Oudenhove L., Simrén M., and Strid H. (2013). "Serum IL-17A in newly diagnosed treatment-naive patients with ulcerative colitis reflects clinical disease severity and predicts the course of disease". *Inflamm Bowel Dis.*19;2433-2439.
- [29] Jiang W., Su J., Zhang X., Cheng X., Zhou J., and Shi R. (2014). "Elevated levels of Th17 cells and Th17-related cytokines are associated with disease activity in patients with inflammatory bowel disease. *Inflammation research : official journal of the European Histamine Research Society*".63(11);943-50.
- [30] Qingdong G., and Jiguo Z. (2017). "Recent Advances: The Imbalance of Cytokines in the Pathogenesis of Inflammatory Bowel Disease". *Mediators of Inflammation*;1-8.
- [31] Cua D., and Tato C. (2010). "Innate IL-17-producing cells: the sentinels of the immune system. *Nat Rev Immunol*".10;479-489.
- [32] Zheng Z., Wan X., and Liu L. (2011). "Serum contents of IL-23 and IL-17 in the patients with ulcerative colitis and the clinical significance". *Xibao Yu Fenzimianyixue Zazhi.*27; 203-206.
- [33] Zhou G., Song Y., and Yang W. (2016). "ASCA, ANCA, ALCA and many more: are they useful in the diagnosis of inflammatory bowel disease?," *Digestive Diseases*".34.1-2; 90-97.
- [34] Bouzid D., Haddouk S., Amouri A., Ben HadjHmida Y., Tahri N, and Masmoudi H. (2011). "Contribution of immunofluorescence to identification and characterization of antineutrophil cytoplasmic antibodies in inflammatory bowel disease. *Indian J Gastroenterol*".30;229-32.
- [35] Prideaux L., de Cruz P., Ng S., and Kamm M. (2012). "Serological antibodies in inflammatory bowel disease: a systematic review," *Inflammatory Bowel Diseases*".18(7);1340-1355.
- [36] Julia S., Ira Elben, Julia D., Glas, M., and Johannes S. (2008). "Role of the Novel Th17 Cytokine IL-17F in Inflammatory Bowel Disease (IBD) Upregulated Colonic IL-17F Expression in Active Crohn's Disease and Analysis of the IL17F p.His161Arg Polymorphism in IBD *Inflamm Bowel Dis*".14(4);437-445.
- [37] Franke A., Hampe J., and Rosenstiel P. (2007). "Systematic association mapping identifies NELL1 as a novel IBD disease gene". *PLoS ONE.*2; e691.
- [38] Cambridge G., Rampton D., Stevens T., McCarthy D., Kamm M, and Leaker B. (1992). "Anti-neutrophil antibodies in inflammatory bowel disease: prevalence and diagnostic role". *Gut* .33;668-674.
- [39] Zauli D., Ghetti S., and Grassi A. (1997). "Anti-neutrophil cytoplasmic antibodies in type 1 and 2 autoimmune hepatitis". *Hepatology.*25;1105-1112.
- [40] Rutgeerts P., and Vermeire S. (1998). "Clinical value of the detection of antibodies in the serum for diagnosis and treatment of inflammatory bowel disease". *Gastroenterology.*115;1006-9.
- [41] Kader H., Ruchelli E., and Maller E. (1998). "Langerhans cell histiocytosis and stool retention caused by a perianal mass". *J Pediatr Gastroenterol Nutr* .26;226-8.
- [42] Dotan I. (2007). "Serologic markers in inflammatory bowel disease: tools for better diagnosis and disease stratification". *Expert Rev Gastroenterol Hepatol.*1; 265-274.
- [43] ZHI Z., KE S. and JIE P. (2017). "Serologic testing of a panel of five antibodies in inflammatory bowel diseases: Diagnostic value and correlation with disease phenotype". *Biomedical Reports.* 6; 401-410.
- [44] Gross W., Schmitt W., and Csernok E. (1993). "ANCA and associated diseases: immunodiagnostic and pathogenetic aspects". *Clin Exp Immunol.*91;1-12.
- [45] Shanahan F., Duerr R., Rotter J., Yang H., Sutherland L., McElree C., Landers C., and Targan S. (1992). "Neutrophil autoantibodies in ulcerative colitis: familial aggregation and genetic heterogeneity. *Gastroenterology*".103;456-461.
- [46] Napolitano G., Perri F., Conoscitore P., and Andriulli A. (2000). "Antineutrophil cytoplasmic antibodies in inflammatory bowel disease: clinical role and review of the literature. *Dis Colon Rectum*".43; 999-1007.
- [47] Peeters M., Joossens S., Vermeire S., Vlietinck R., Bossuyt X., and Rutgeerts P. (2001). "Diagnostic value of anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease". *Am J Gastroenterol.*96;730-4.
- [48] Abu-Freha N., Wafi B., Ina S., Muhammad Abu T., Ohad E., Jaber E., Afzali B., Lombardi G., Lechler R., Lord G. (2007). "The role of T helper 17 (Th17) and regulatory T cells (Treg) in human organ transplantation and autoimmune disease". *Clin Exp Immunol.*148;32-46.
- [49] Saibeni S., and GBorsi M. (2003). "Diagnostic role and clinical correlates of anti-Saccharomyces cerevisiae antibodies (ASCA) and anti-neutrophil cytoplasmic antibodies (p-ANCA) in Italian patients with inflammatory bowel diseases Author links open overlay panel. *Digestive and Liver Disease*".35(12);862-868
- [50] Zhou F., Xia B., and Wang F. (2010). "The prevalence and diagnostic value of perinuclear antineutrophil cytoplasmic antibodies and anti-Saccharomyces cerevisiae antibodies in patients with inflammatory

bowel disease in mainland China". Clinica Chimica
Acta.411(20); 1461-1465.

دراسة بعض المؤشرات المناعية لدى مرضى التهاب الأمعاء (IBD) في محافظة الانبار

ذكرى ماجد محمد فرج العبيدي¹ وحسن علي مطر² وثائر عبد القادر صالح³

¹قسم علوم الحياة , كلية العلوم, جامعة الانبار/الرمادي, العراق , ² قسم الانتاج الحيوانية, كلية الزراعة, جامعة الانبار/الرمادي, العراق .
³ قسم علوم الحياة , كلية التربية للعلوم الصرفة جامعة الانبار/الرمادي, العراق .

الخلاصة:

تم تحديد المستويات المصلية لكل من الحركي الخلوي IL-17A و IL-17F باستخدام تقنية الامتزاز المناعي المرتبط بالإنزيم (ELISA), حيث أجريت مقارنة المتغيرات المناعية بين مجموعتي المرضى والسيطرة, حيث بينت النتائج هناك زيادة معنوية بين مجموعة المرضى ومجموعة السيطرة لكلا من الحركي الخلوي IL-17 A و IL-17F عند مستوى معنوية ($P < 0.05$) إذ كان المتوسط العام لكلا من المتغيرات: IL-17F (18.72 pg/ml), IL-17 A (79.29 pg/ml) (29.09 pg/ml), (226.4 pg/ml) كذلك تم تحديد المستويات المصلية لكل من الاجسام المضادة pANCA و c ANCA باستخدام تقنية الامتزاز المناعي المرتبط بالإنزيم (ELISA), حيث اظهرت هذه الدراسة ايضا وجود فرق معنوي بين المجموعتين لكلا من الاجسام المضادة الذاتية, الاجسام المضادة الذاتية للغلاف المحيط بالنواة لخلايا الدم البيض العدلة pANCA والاجسام المضادة الذاتية للسيتوبلازم لخلايا الدم البيض العدلة c ANCA عند مستوى معنوية ($P < 0.05$) إذ كان المتوسط العام لكلا من المتغيرات: c ANCA (35.78 ng/ml), (8.341ng/ml). \ pANCA (60.93 ng/ml), (10.31ng/ml).